Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)

NCT ID: NCT00126321

Last Updated: 2010-02-02

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-11-30
• Study Completion Date: 2011-03-31

Brief Summary

The purpose of this study is to evaluate the safety and the efficacy of cladribine, high-dose cytarabine and idarubicin in the treatment of patients with relapsed acute myeloid leukemia.

Detailed Description

Considerable progress has been made in the induction therapy of acute myeloid leukemia (AML); however, current therapeutic results are still unsatisfactory in those with relapsed disease. The purine nucleoside analogue cladribine (2-chlorodeoxyadenosine, 2-CdA) has been shown to be a safe and active agent in acute myeloid leukemia. Synergistic interaction between cladribine and cytarabine has been demonstrated in preclinical and clinical studies.

The current multicenter phase II study was initiated to evaluate the efficacy and toxicity of cladribine, high-dose cytarabine, and idarubicin in the treatment of patients with relapsed AML. Adult patients of all age groups can be enrolled in the trial, but elderly patients will be treated with a less dose-intensive regimen.

Conditions

Leukemia, Myelocytic, Acute

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

cladribine

2-chlorodeoxyadenosine, 2-CdA

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients with relapsed AML with a remission duration of at least 6 months after first complete remission (CR) or of at least 3 months after second (or higher) CR
• Age >= 18 years
• Life expectancy of at least three months (without consideration of AML and complications)
• Eastern Cooperative Oncology Group (ECOG) 0-2 (without consideration of AML and complications)
• Written informed consent

Exclusion Criteria

• Prior therapy of AML with cladribine
• Severe, uncontrolled infection at time of inclusion (enrollment is possible after control of infection)
• Cardiac insufficiency grade III or IV New York Heart Association (NYHA)
• Severe renal insufficiency with a clearance of < 30 ml/min (if not due to AML)
• Severe hepatic insufficiency with bilirubin > 3 mg/dl or AST > 200 U/l (if not due to AML)
• Other severe organ impairment grade III or IV World Health Organization (WHO) (if not due to AML or, in the opinion of the investigator, may not interfere with the procedures in the study)
• HIV infection
• Intolerance to study drugs
• Pregnant or breast-feeding women
• Any other malignant disease which will probably affect the course of AML

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital, Bonn

OTHER

Sponsor Role: lead

Responsible Party

University Hospital, Med. Klinik III, Bonn, Germany

Principal Investigators

Marie von Lilienfeld-Toal, MD

Role: PRINCIPAL_INVESTIGATOR

Medical Clinic & Policlinic III, University Hospital Bonn

Locations

Medical Clinic & Policlinic III, University Bonn

Bonn, , Germany

Site Status: RECRUITING

Countries

Germany

Central Contacts

Axel Glasmacher, MD

Role: CONTACT

glasmacher@uni-bonn.de

+49-228-287-15507

Facility Contacts

Marie von Lilienfeld-Toal, MD

Role: primary

m.lilienfeld.toal@uni-bonn.de

+49-228-287-22263

Other Identifiers

CAI

Identifier Type: -

Identifier Source: org_study_id